subscribeSubscribe
FDA Confirms Para IV Patent Litigation for Lasmiditan Succinate (Reyvow) Tablets

FDA Confirms Para IV Patent Litigation for Lasmiditan Succinate (Reyvow) Tablets
FDA
26 Mar 2024
Share Share
Eli Lilly`s Rayvow (lasmiditan) Receives Approval in Europe

Eli Lilly`s Rayvow (lasmiditan) Receives Approval in Europe
EMA
03 Oct 2022
Share Share
Eli Lilly, Daiichi Sankyo partner to commercialize lasmiditan succinate in Japan

Eli Lilly, Daiichi Sankyo partner to commercialize lasmiditan succinate in Japan
PHARMABIZ
31 Aug 2021
Share Share
REYVOW® Positive Data in New Phase 3 Consistency of Effect Study

REYVOW® Positive Data in New Phase 3 Consistency of Effect Study
PRNEWSWIRE
06 Oct 2020
Share Share
Eli Lilly`s Reyvow, squaring off against AbbVie and Biohaven

Eli Lilly`s Reyvow, squaring off against AbbVie and Biohaven
Eric Sagonowsky FIERCE PHARMA
11 Sep 2020
Share Share
Lilly`s migraine med lasmiditan successful in another late-stage study

Lilly`s migraine med lasmiditan successful in another late-stage study
SEEKINGALPHA
10 Sep 2020
Share Share
ICER comes around on Allergan, Biohaven migraine meds

ICER comes around on Allergan, Biohaven migraine meds
E. Sagonowsky FIERCE PHARMA
26 Feb 2020
Share Share
Eli Lilly prices migraine therapy at $640 for pack of eight pills

Eli Lilly prices migraine therapy at $640 for pack of eight pills
REUTERS
31 Jan 2020
Share Share
With DEA scheduling, Lilly`s Reyvow cleared for launch

With DEA scheduling, Lilly`s Reyvow cleared for launch
Eric Sagonowsky FIERCE PHARMA
31 Jan 2020
Share Share
Lilly`s REYVOW™C-V, the First and Only Medicine in Acute Treatment for Migraine

Lilly`s REYVOW™C-V, the First and Only Medicine in Acute Treatment for Migraine
PRESS RELEASE
31 Jan 2020
Share Share